Sertindole in schizophrenia: efficacy and safety issues. (Q38236032)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25084209%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

title

Sertindole in schizophrenia: efficacy and safety issues (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25084209%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

Maria Rosaria Anna Muscatello

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25084209%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Gianluca Pandolfo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25084209%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Antonio Bruno

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25084209%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Paolo Micali Bellinghieri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25084209%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Rocco Antonio Zoccali

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25084209%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

language of work or name

English

0 references

publication date

1 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25084209%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

11 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25084209%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25084209%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25084209%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

1943-1953

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25084209%20AND%20SRC:MED&resulttype=core&format=json

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

11 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Phenotype of schizophrenia: a review and formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Social cognitive impairments and negative symptoms in schizophrenia: are there subtypes with distinct functional correlates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Clozapine resistance--augmentation strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Sertindole: efficacy and safety in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Sertindole: dilemmas for its use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Sertindole for the treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Drug safety and efficacy evaluation of sertindole for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Pharmacokinetics of sertindole in healthy young and elderly male and female subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Sertindole in the long-term treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat--a back translational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Effects of olanzapine, sertindole and clozapine on MK-801 induced visual memory deficits in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Comparison of the effects of Sertindole and Olanzapine on Cognition (SEROLA): a double-blind randomized 12-week study of patients diagnosed with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

QTc prolongation, torsades de pointes, and psychotropic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Sertindole causes distinct electrocardiographic T-wave morphology changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

The effect of sertindole on QTD and TPTE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

The Sertindole Safety Survey: a retrospective analysis under a named patient use programme in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Sertindole: safety and tolerability profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

A review of the efficacy, tolerability and safety of sertindole in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960

Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.947960